Analysts Adjust Price Target on Stereotaxis Amid Production Challenges
Stereotaxis (STXS) faces production constraints with its MAGiC catheter, leading Piper Sandler to lower its price target from $4.0 to $3.5 while maintaining an 'Overweight' rating. The company reported Q1 revenue of $6.3 million and highlighted progress in regulatory approvals for new products.
Topics: FDA approval MAGiC catheter Piper Sandler revenue report Stereotaxis